Anti-CD20 antibodies, including rituximab, obinutuzumab, and ofatumumab, are central in chronic lymphocytic leukemia (CLL), while alemtuzumab, which targets CD52, remains an option for refractory disease [151]. The gene discussed is CD52; the disease is B-cell chronic lymphocytic leukemia.